A phase II study of Dactinomycin for treatment of NPM1-Mutated acute myeloid leukemia (AML) patients.
Phase of Trial: Phase II
Latest Information Update: 03 Jan 2018
Price : $35 *
At a glance
- Drugs Dactinomycin (Primary)
- Indications Acute myeloid leukaemia
- Focus Therapeutic Use
- 03 Jan 2018 Results (n=9) published in the Rasna Therapeutics Media Release.
- 15 May 2017 New trial record